http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001513500-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 1998-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001513500-A |
| titleOfInvention | Use of an NK-1 receptor antagonist for the treatment of mania |
| abstract | (57) [Summary]nThe present invention relates to the use of an orally active, long acting CNS-permeable NK-1 receptor antagonist, optionally with an antipsychotic, for the manufacture of a medicament for the treatment or prevention of mania or hypomania. The present invention provides a method for treating the NK-1 receptor antagonist, a therapeutic method using the NK-1 receptor antagonist, and a pharmaceutical composition and a product containing the same. |
| priorityDate | 1997-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.